                         SEQUENCE LISTING

<110>  Artificial Cell Technologies, Inc.
       Powell, Thomas J
 
<120>  ANTI-MALARIA COMPOSITIONS AND METHODS

<130>  ATE0022US2

<150>  61/617998
<151>  2012-03-30

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  16
<212>  PRT
<213>  Plasmodium falciparum

<400>  1

Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val 
1               5                   10                  15      


<210>  2
<211>  4
<212>  PRT
<213>  Plasmodium falciparum

<400>  2

Asn Ala Asn Pro 
1               


<210>  3
<211>  20
<212>  PRT
<213>  Plasmodium falciparum

<400>  3

Glu Tyr Leu Asn Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro 
1               5                   10                  15      


Cys Ser Val Thr 
            20  


<210>  4
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer

<400>  4
aagcattaaa taaagcgaat acatccttac                                        30


<210>  5
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer

<400>  5
ggagattggt tttgacgttt atgtg                                             25


<210>  6
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  6

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys Tyr 
            20      


<210>  7
<211>  73
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  7

Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val 
1               5                   10                  15      


Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Glu Tyr Leu Asn 
            20                  25                  30          


Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro Cys Ser Val Thr 
        35                  40                  45              


Ser Gly Asn Gly Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
    50                  55                  60                  


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
65                  70              


<210>  8
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  8

Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val 
1               5                   10                  15      


Asp Pro Asn Ala Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
            20                  25                  30          


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
        35                  40      


<210>  9
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  9

Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro 
1               5                   10                  15      


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
            20                  25                  30          


Lys Lys Lys Lys Tyr 
        35          


<210>  10
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  10

Glu Tyr Leu Asn Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro 
1               5                   10                  15      


Cys Ser Val Thr Ser Gly Asn Gly Lys Lys Lys Lys Lys Lys Lys Lys 
            20                  25                  30          


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
        35                  40                  45  


<210>  11
<211>  53
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  11

Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val 
1               5                   10                  15      


Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro 
            20                  25                  30          


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
        35                  40                  45              


Lys Lys Lys Lys Tyr 
    50              


<210>  12
<211>  61
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  12

Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val 
1               5                   10                  15      


Glu Tyr Leu Asn Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro 
            20                  25                  30          


Cys Ser Val Thr Ser Gly Asn Gly Lys Lys Lys Lys Lys Lys Lys Lys 
        35                  40                  45              


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
    50                  55                  60      


<210>  13
<211>  57
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  13

Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Glu Tyr Leu Asn 
1               5                   10                  15      


Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro Cys Ser Val Thr 
            20                  25                  30          


Ser Gly Asn Gly Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
        35                  40                  45              


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
    50                  55          


<210>  14
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  14

Leu Glu Phe Val Lys Gln Ile Arg Asp Ser Ile Thr Glu Glu Trp Ser 
1               5                   10                  15      


Gln Cys Asn Val Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
            20                  25                  30          


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
        35                  40      


<210>  15
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  15

Lys Asn Asn Asn Asn Asp Asp Ser Tyr Ile Pro Ser Ala Glu Lys Ile 
1               5                   10                  15      


Leu Glu Phe Val Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
            20                  25                  30          


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
        35                  40      


<210>  16
<211>  57
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  16

Lys Asn Asn Asn Asn Asp Asp Ser Tyr Ile Pro Ser Ala Glu Lys Ile 
1               5                   10                  15      


Leu Glu Phe Val Lys Gln Ile Arg Asp Ser Ile Thr Glu Glu Trp Ser 
            20                  25                  30          


Gln Cys Asn Val Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
        35                  40                  45              


Lys Lys Lys Lys Lys Lys Lys Lys Tyr 
    50                  55          


<210>  17
<211>  70
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Designed peptide

<400>  17

Ser Lys Lys Lys Lys Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn 
1               5                   10                  15      


Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn 
            20                  25                  30          


Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn 
        35                  40                  45              


Pro Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
    50                  55                  60                  


Lys Lys Lys Lys Lys Tyr 
65                  70  


